Recall Alert; Drug Product: Phenerzine Elixir (Batch # 037) by M/s Epoch Pharmaceuticals (Pvt) Ltd., Karachi

Recall Alert

DRAP Alert NoNoII/S/07-22-20
Action Date2nd August, 2022
Target Audience1. Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
2. Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospitals, clinics and healthcare institutions
3. General Public
Product(s) Affected Phenerzine Elixir,
Company: M/s Epoch Pharmaceuticals (Pvt) Ltd., Karachi
Batch No. 037
Manufacturing Date: March-2022,
Expiry Date: March-2024
Problem StatementThe Central Drug Laboratory Karachi has analyzed the sample of Phenerzine Elixir bearing Batch No. 037 and declared it as Adulterated and Substandard. The company has been directed to recall the affected batch of product from the market.
Action to be taken-All Pharmacists and chemists working at distributions and Pharmacies are required to immediately return the stock of above mentioned batch of product to the company.

-Distributors and pharmacies are advised to be vigilant and report any suspected batch of product(s) in the supply chain to the DRAP using online form, or through phone at +92 51 910 73 17, or Email at gsms@dra.gov.pk.

-Regulatory field force of all federating units (DRAP, Provincial Health Departments and States) have also increased surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals-DRAP requests increased vigilance within the supply chains of healthcare institutions and hospital pharmacies.

-Adverse reactions or quality problems experienced with the use of this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using this product bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

All drug products must be obtained from authorized licensed sources/outlets. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of any doubt.

Recall Alert; Drug Product: Faasgablin 75mg Capsules (Batch # 2210C001) by M/s FAAS Pharmaceuticals (Pvt) Ltd., Karachi

Recall Alert

DRAP Alert NoNoII/S/07-22-19
Action Date28th July, 2022
Target Audience1. Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
2. Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospitals, clinics and healthcare institutions
3. General Public
Product(s) Affected Faasgablin 75mg capsules,
Company: M/s FAAS Pharmaceuticals (Pvt) Ltd., Karachi
Batch No. 2210C001
Manufacturing Date: January-2022,
Expiry Date: January-2024
Problem StatementThe Central Drug Laboratory Karachi has analyzed the sample of Faasgablin 75mg capsules bearing Batch No. 2210C001 and declared it as Substandard. The company has been directed to recall the affected batch of product from the market.
Action to be taken-All Pharmacists and chemists working at distributions and Pharmacies are required to immediately return the stock of above mentioned batch(s) of product to the company.

-Distributors and pharmacies are advised to be vigilant and report any suspected batch of product(s) in the supply chain to the DRAP using online form, or through phone at +92 51 910 73 17, or Email at gsms@dra.gov.pk.

-Regulatory field force of all federating units (DRAP, Provincial Health Departments and States) have also increased surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals-DRAP requests increased vigilance within the supply chains of healthcare institutions and hospital pharmacies.

-Adverse reactions or quality problems experienced with the use of this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link.

-Please click here for further information on problem reporting to DRAP.
Advice for Consumers-Consumers should stop using this product bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

All drug products must be obtained from authorized licensed sources/outlets. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of any doubt.

Recall Alert: Drug Product; Water for Injection (Batch #M21421) by M/s. Vision Pharmaceuticals (Pvt.) Ltd., Islamabad.

Recall Alert

DRAP Alert NoN0 I/S/06-22-16
Action Date14th June, 2022
Target Audience1. Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
2. Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospitals, clinics and healthcare institutions
3. General Public
Product(s) Affected Water for Injection,
Company: M/s. Vision Pharmaceuticals (Pvt.) Ltd., Islamabad
Drug Registration No. 081230
Batch No. M21421,
Manufacturing Date: December-2021,
Expiry Date: November-2024
Problem StatementThe Central Drug Laboratory Karachi has analyzed the Water for injection bearing Batch No. M21421 4A20B27 and declared it as Substandard. The company has been directed to recall the affected batch of product from the market including pharmacies as well as the distribution setups operating in the country.
Action to be takenAll Pharmacists and chemists working at distributions and Pharmacies are required to immediately return the stock of above mentioned batch of the product(s) to the firm. Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP at +92 51 910 73 17, or Email at gsms@dra.gov.pk.
Regulatory field force of all federating units (DRAP, Provincial Health Departments and States) have also increased surveillance in the market to ensure the effective recall of defective product.
Advice for Healthcare ProfessionalsDRAP requests increased vigilance within the supply chains of healthcare institutions and hospital pharmacies.

If anyone has used this counterfeit product, or if anyone suffers from an adverse reaction/event after having used this product, it is advised to seek immediate medical attention from a qualified healthcare professional, and to report the incident to National Pharmacovigilance Centre, DRAP using this link.

All drug products must be obtained from authorized licensed sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of any doubt.

Voluntary Recall Alert: Drug Product; Meronem 1g Injection (Batch #4A20B27 and Batch # 4A21D29) by M/S. Pfizer Pakistan Limited, Karachi

Voluntary Recall Alert

DRAP Alert NoN0 I/V/ 15-22-05
Action Date18th May, 2022
Target Audience1. Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
2. Healthcare Processionals- Physicians, Pharmacists and Nurses at hospitals and clinics
3. General Public
Products Affected Meronem 1g Injection (Intravenous) ,
Batch No. 4A20B27, Expiry Date: August-2022
4A21D29, Expiry Date: December-2023
Problem StatementM/s. Pfizer Pakistan Limited, Karachi has confirmed from their own sources that there is counterfeit Meronem 1gm Injection bearing Batch No. 4A20B27 and 4A21D29, in the market with similar packaging and appearance of their registered product. Due to this, M/s Pfizer Pakistan Limited has initiated a nation wide voluntary recall of 02 batches of their registered product of same batch numbers from the market up to pharmacies and distribution level. Company may be contacted at M/s Pfizer Pakistan Limited, B-2, S.I.T.E, Karachi-75700, Ph +92 (21) 32570621-5
Action to be takenAll Pharmacists and chemists working at distributions and Pharmacies are required to immediately return the stock of above mentioned batches of Meronem 1g injections to the firm, company is also communicating distributors through this letter. Distributors and pharmacies are advised to be vigilant and report any suspected product(s) to the DRAP. Regulatory field force of all federating units (DRAP, Provincial Health Departments and States) have also increased surveillance to ensure the integrity of supply chain.
Advice for Healthcare ProfessionalsDRAP requests increased vigilance within the supply chains of healthcare institutions and hospital pharmacies.

If anyone has used this counterfeit product, or if anyone suffer an adverse reaction/event having used this product batch, it is advised to seek immediate medical advice from a qualified healthcare professional, and to report the incident to Drug Regulatory Authority of Pakistan/National Pharmacovigilance Centre using this link.

All drug products must be obtained from authorized licensed sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional in case of any doubt.